DRR168533
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- ALLOGRAFT_REJECTION+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- IL6_JAK_STAT3_SIGNALING+0.410
- INTERFERON_ALPHA_RESPONSE+0.400
- INFLAMMATORY_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.370
- COMPLEMENT+0.330
- E2F_TARGETS+0.290
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- OXIDATIVE_PHOSPHORYLATION-0.450
- MYC_TARGETS_V1-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.350
- DNA_REPAIR-0.330
- GLYCOLYSIS-0.280
- NOTCH_SIGNALING-0.230
- WNT_BETA_CATENIN_SIGNALING-0.210
- ADIPOGENESIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG68 | — | — | 0.858 |
| 2 | SRR23303766 | — | — | 0.848 |
| 3 | GSM5359446 | — | — | 0.841 |
| 4 | SRR818270 | GTEX | — | 0.835 |
| 5 | MNG1166 | — | — | 0.829 |
| 6 | SRR821690 | GTEX | — | 0.823 |
| 7 | SRR615467 | GTEX | — | 0.819 |
| 8 | MNG276 | — | — | 0.817 |
| 9 | R263 | — | — | 0.816 |
| 10 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |